Form 4: Minerva director granted 9,500 stock options

Minerva Neurosciences director Inderjit Kaul received 9,500 stock options at a $4.11 strike, vesting quarterly over three years.

Summary

• Director Inderjit Kaul received a grant of stock options to purchase 9,500 shares of Minerva Neurosciences common stock.
• Exercise price is $4.11 per share; the grant date is 11/14/2025.
• Options vest in equal quarterly installments over three years, with the first vesting on 02/14/2026, contingent on continued service as a non-employee director.
• Options expire on 11/13/2035 if unexercised.
• Price of derivative security reported as $0 for the grant; post-transaction beneficial ownership of derivative securities is 9,500, held directly.

Sentiment

Score: 5

Explanation: A routine, neutral insider option grant that modestly aligns incentives but has minimal immediate impact; minor potential dilution.

Positives

• Equity grant aligns the director’s incentives with shareholders via performance-linked upside.
• Three-year, quarterly vesting supports board member retention through 2028.
• At-the-money strike price of $4.11 is consistent with standard governance practices for option grants.

Negatives

• Potential dilution of up to 9,500 shares upon exercise.
• No operational, financial, or strategic updates are provided.
• Vesting is contingent on continued service; the award may not fully vest if board service ends early.

Risks

• Options vest only if the director continues serving as a non-employee director through each vesting date.

Future Outlook

No financial guidance or operational outlook is provided; only the vesting schedule and expiration for the granted options are specified.

Industry Context

Routine equity-based compensation for non-employee directors is standard across U.S. biotech companies; size, at-the-money pricing, and multi-year vesting are typical structures.

Comparison to Industry Standards

• Grant size: 9,500 options is within the common range for small-cap biotech director annual equity awards, which often fall in the mid-thousands to tens of thousands of shares.
• Vesting: Three-year quarterly vesting is a standard cadence among U.S. biotech peers, aligning with practices at companies such as Acadia Pharmaceuticals (ACAD), Sage Therapeutics (SAGE), and Karuna Therapeutics (KRTX).
• Pricing: At-the-money strike pricing on the grant date is consistent with U.S. corporate governance norms for equity awards to independent directors.

Related Party Transactions

• Grant of 9,500 stock options to non-employee director Inderjit Kaul at a $4.11 exercise price, vesting quarterly over three years.

Stakeholder Impact

• Shareholders: Minor potential dilution (9,500 shares) if options are exercised.
• Directors: Increased equity-based compensation enhances alignment with long-term shareholder value.
• Employees, customers, suppliers, creditors: No direct impact disclosed.

Next Steps

• Quarterly vesting to commence on 02/14/2026, subject to continued service.
• Options remain exercisable per grant terms until 11/13/2035, if vested.

Key Dates

Keywords

Minerva Neurosciences, NERV, Form 4, insider transaction, stock option grant, director compensation, vesting schedule, beneficial ownership, exercise price, equity incentives